Market Context — Why This Technology, Why Now

The increasing global emphasis on preventive healthcare and personalized medicine is fueling demand for non-invasive diagnostic solutions. Regulatory bodies are also encouraging technologies that improve patient quality of life and reduce healthcare costs. Furthermore, competitive pressures in the oncology sector are pushing for faster, more accurate, and less burdensome methods for early detection and treatment monitoring, making this technology a timely and strategic investment for market leaders.

Key Competitive Advantages
01

Significantly reduces patient burden, enabling less invasive diagnostic alternatives or complements to biopsies and imaging.

02

Enables rapid, frequent monitoring of tumor changes over time, aiding in treatment efficacy assessment and early recurrence detection.

03

Utilizes novel antioxidant capacity biomarkers in serum, potentially detecting tumors missed by conventional markers.

Market Opportunity
Cancer Screening Market
$15B–$20B globally (AI est.)
Low invasiveness makes it easier for more healthy individuals to undergo regular screening, contributing to improved early detection rates. Expected to be introduced into comprehensive health check-ups and general health screenings.
Large diagnostic laboratories Health check-up providers Medical device manufacturers for screening
Treatment Efficacy Monitoring Market
$2B–$4B globally (AI est.)
Because it allows for rapid, time-series evaluation, it can help grasp tumor changes in patients undergoing treatment in near real-time, aiding in optimizing treatment methods and early detection of side effects.
Oncology clinics and hospitals Pharmaceutical companies for clinical trials Diagnostic imaging companies
Drug Discovery and Clinical Development Support Market
$2B–$4B globally (AI est.)
By providing non-invasive and quantitative evaluation indicators for drug efficacy assessment and biomarker discovery, it has the potential to contribute to the efficiency of clinical trials and shortening development periods.
Contract Research Organizations (CROs) Pharmaceutical R&D divisions Biotech companies developing oncology drugs
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a comprehensive method for acquiring and utilizing data for tumor evaluation, specifically detailing the measurement process of antioxidant capacity changes in serum. Its successful grant, overcoming four cited prior art documents, indicates strong novelty and inventive step, establishing a robust and stable intellectual property foundation.

Competitive White Space

This patent primarily covers the method for data acquisition and utilization. White space exists for developing novel hardware for antioxidant measurement, advanced AI/ML algorithms for predictive analytics, or integrated digital health platforms.

Economic Impact
~$1M/year estimated medical cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

By integrating this technology, companies could reduce the frequency of invasive procedures (e.g., biopsies at ~$0.7K/procedure (AI est.)) from 5 to 3 times annually per patient, saving ~$1.5K/patient (AI est.). Applying this to 500 patients annually yields ~$750K (AI est.) in savings. Additionally, a 20% reduction in physician/technician time for test preparation and analysis could generate ~$150K (AI est.) in efficiency, totaling over ~$900K (AI est.) in annual savings.

Speed to Market
6× faster than in-house development
This technology is patented as a 'method for acquiring data for tumor evaluation,' with its principles well-established. Since existing clinical laboratory equipment can already measure free radicals and antioxidant capacity in serum, extensive new equipment development is unnecessary. By integrating with existing measurement technologies, efforts can focus on protocol design and clinical prototype validation, significantly accelerating time to market.
Competitive Positioning

X: Patient Burden Reduction
Y: Early Detection Accuracy

Business Models & Applications
🤝 Technology Licensing
License this patented technology to medical device manufacturers or contract research organizations to integrate into existing products/services, securing royalty revenue.
🔬 Collaborative R&D
Engage in joint research with the university to optimize diagnostic algorithms for specific cancer types or explore new clinical applications, maximizing technology value.
💡 Diagnostic Service Offering
Potentially establish a new revenue stream by offering high-precision tumor evaluation services to medical institutions and health check-up centers using this technology.
Adjacent Application Opportunities
🩺 健康診断・予防医療
Integrate into Routine Health Screenings
By integrating this technology into existing blood test items, it could offer a "next-generation cancer screening" service that is minimally invasive and simple for cancer risk assessment. This is expected to significantly increase early detection opportunities and enhance the quality of preventive medicine.
🐾 ペット医療
Animal Cancer Diagnostics
Similar to humans, cancer incidence in pets is rising with aging. In veterinary clinics, this blood-sample-only technology could serve as an innovative, low-stress cancer diagnostic tool for pets, likely gaining easier owner consent.
🔬 創薬支援
Efficacy Measurement in Drug Development
In oncology drug clinical trials, this technology could serve as an objective biomarker for treatment efficacy. Non-invasive drug effectiveness assessment is expected to shorten development times and reduce costs.
Integration Roadmap — Estimated 31-Month Deployment
Technology Compatibility & Protocol Design
Duration: 4 months
Evaluate technical compatibility with the licensee's existing testing equipment and systems, then design specific protocols and data analysis flows for integrating this technology.
System Development & Clinical Validation
Duration: 9 months
Develop data acquisition and analysis systems based on the designed protocols. Subsequently, conduct small-scale clinical validation to obtain initial data on the technology's efficacy and safety.
Regulatory Approval & Market Rollout
Duration: 18 months
Utilize data from clinical validation to pursue regulatory approval as a medical device. Following approval, initiate full-scale market rollout and service provision to accelerate adoption.
Technical Feasibility
This technology, centered on 'measuring changes in antioxidant capacity' and 'measuring free radicals in serum,' can be technically integrated into existing blood analyzers and automated biochemical analyzers commonly used in clinical laboratories. Minimal new dedicated equipment investment is required, as the primary adjustments involve software and reagent systems, indicating high compatibility with existing diagnostic infrastructure and low technical barriers to adoption.
Success Scenario
Adopting this technology could allow companies to monitor tumor progression more frequently while significantly reducing physical burden on patients. This may improve cancer early detection rates and enhance patient prognosis through earlier therapeutic intervention. Rapid assessment of treatment efficacy could also enable flexible adjustments to optimize treatment plans, contributing to efficient healthcare resource utilization and cost containment.
Patent Record
APPLICATION NO.
特願2021-013937
REGISTRATION NO.
7460160
FILING DATE
2021/01/29
GRANT DATE
2024/03/25
EXPIRATION DATE
2041/01/29
PATENT HOLDER
国立大学法人福井大学
Examination History
2023年09月06日
出願審査請求書
2024年03月05日
特許査定